Halozyme Therapeutics (HALO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.28
- EPS estimate
- $1.79
- EPS surprise
- +27.58%
- Revenue surprise
- +19.57%
- Revenue
- $481.0M
- Revenue estimate
- $402.3M
- Reported
- Aug 6, 2026
Halozyme reported Q2 2026 results on August 6, 2026. Earnings per share were $2.28, beating the $1.79 estimate by 27.58%. Revenue reached $481.0 million against a $402.3 million consensus, a 19.57% beat. Both figures are the highest in the table. Compared with Q2 2025, EPS rose about 48% from $1.54 and revenue rose about 48% from $325.7 million.
The longer record shows strong growth with one break. Annual EPS rose from $1.45 in 2022 to $2.78 in 2023 and $4.23 in 2024, then slipped to $4.13 in 2025. That 2025 total includes a Q4 loss of $0.24 per share against a $2.16 estimate, even as revenue reached $451.8 million. Annual revenue grew each year, from $660.2 million in 2022 to $1.40 billion in 2025. The first half of 2026 brought $3.88 per share, about 46% more than a year earlier. Halozyme topped the EPS estimate in 16 of the last 20 quarters.
Halozyme reported Q3 between October 31 and November 8 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue stays near the Q2 level.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $1.79 | $2.28 | +27.58% | $481.0M | SEC |
| Q1 2026 | May 11, 2026 | $1.55 | $1.60 | +3.56% | $376.7M | SEC |
| Q4 2025 | Feb 17, 2026 | $2.16 | −$0.24 | −111.11% | $451.8M | SEC |
| Q3 2025 | Nov 3, 2025 | $1.63 | $1.72 | +5.51% | $354.3M | SEC |
| Q2 2025 | Aug 5, 2025 | $1.27 | $1.54 | +21.42% | $325.7M | SEC |
| Q1 2025 | May 6, 2025 | $0.95 | $1.11 | +17.04% | $264.9M | SEC |
| Q4 2024 | Feb 18, 2025 | $1.16 | $1.26 | +8.78% | $298.0M | SEC |
| Q3 2024 | Oct 31, 2024 | $0.99 | $1.27 | +28.11% | $290.1M | SEC |
| Q2 2024 | Aug 6, 2024 | $0.76 | $0.91 | +19.96% | $231.4M | SEC |
| Q1 2024 | May 7, 2024 | $0.69 | $0.79 | +15.08% | $195.9M | SEC |
| Q4 2023 | Feb 20, 2024 | $0.83 | $0.82 | −0.61% | $230.0M | SEC |
| Q3 2023 | Nov 6, 2023 | $0.71 | $0.75 | +6.20% | $216.0M | SEC |
| Q2 2023 | Aug 8, 2023 | $0.63 | $0.74 | +17.46% | $221.0M | SEC |
| Q1 2023 | May 9, 2023 | $0.38 | $0.47 | +22.88% | $162.1M | SEC |
| Q4 2022 | Feb 21, 2023 | $0.30 | $0.42 | +40.61% | $181.5M | SEC |
| Q3 2022 | Nov 8, 2022 | $0.36 | $0.44 | +21.65% | $209.0M | SEC |
| Q2 2022 | Aug 9, 2022 | $0.47 | $0.16 | −65.96% | $152.4M | SEC |
| Q1 2022 | May 10, 2022 | $0.46 | $0.43 | −6.79% | $117.3M | SEC |
| Q4 2021 | Feb 22, 2022 | $0.38 | $0.46 | +19.57% | $102.0M | SEC |
| Q3 2021 | Nov 2, 2021 | $0.42 | $1.48 | +249.47% | $115.8M | — |
Quarterly revenue
Frequently asked questions
When did Halozyme Therapeutics (HALO) last report earnings?
Halozyme Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did HALO beat earnings estimates?
Yes. Halozyme Therapeutics reported EPS of $2.28 for Q2 2026 against a $1.79 estimate — a 27.58% beat.
How much revenue did HALO report last quarter?
Halozyme Therapeutics reported $481.0M in revenue for Q2 2026, against a consensus estimate of $402.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.